Pharmaceutical Industry's Adoption of AI Accelerates Drug Development, but Raises Concerns about Equity and Access
Original framing: “J&J sees AI halving the time to generate drug development leads - Reuters” — Reuters (via Google News)
The pharmaceutical industry has a long history of exploiting colonial and imperial relationships to access traditional knowledge and resources. The adoption of AI in drug development perpetuates this legacy of exploitation, particularly if the benefits of these treatments are not shared equitably with marginalized communities.
The adoption of AI in drug development has the potential to significantly reduce the time and cost associated with generating leads, but it also raises concerns about equity and access to these life-saving treatments.
The pharmaceutical industry's reliance on AI may exacerbate existing health disparities, particularly in low-resource settings. Furthermore, the lack of transparency and accountability in AI-driven decision-making processes may perpetuate biases and inequalities. To address these challenges, the industry should establish clear guidelines and protocols for ensuring equitable access to AI-driven treatments, respect traditional knowledge and practices, and prioritize the development of AI-driven treatments that are culturally sensitive and tailored to the specific needs of marginalized communities.